Idiopathic inflammatory myopathy
Myositis · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A group of autoimmune muscle diseases including dermatomyositis, polymyositis, immune-mediated necrotising myopathy and inclusion body myositis, presenting with proximal weakness and raised creatine kinase. Associated with malignancy, interstitial lung disease and specific myositis antibodies that guide prognosis.
Red flags
- Respiratory muscle weakness or rapidly progressive ILD (especially anti-MDA5)
- Dysphagia with aspiration risk
- Associated malignancy (TIF1-gamma antibody)
- Rhabdomyolysis with renal impairment
- Cardiac involvement
Assessment
Differential diagnosis
- Inclusion body myositis (distal/asymmetric, treatment-resistant)
- Muscular dystrophy
- Statin-associated or toxic myopathy
- Endocrine myopathy (thyroid, Cushing's)
- Motor neuron disease
- Metabolic myopathy
Investigations
- Creatine kinase (markedly elevated except in IBM)
- EMG (myopathic units with irritability)
- Myositis-specific and associated antibodies (Jo-1, Mi-2, MDA5, HMGCR, SRP, TIF1-gamma)
- MRI muscle to guide biopsy
- Muscle biopsy for definitive diagnosis
- Malignancy screen (especially dermatomyositis) and HRCT chest for ILD
Management
- Recognise subacute symmetrical proximal weakness with raised creatine kinase
- Look for dermatomyositis skin signs (Gottron's papules, heliotrope rash)
- Confirm with EMG, MRI-guided muscle biopsy and myositis antibodies
- Screen for associated malignancy and interstitial lung disease
- Assess swallowing and respiratory muscle function
- Start high-dose corticosteroids as first-line therapy
- Add a steroid-sparing immunosuppressant early
- Use IVIG for severe, refractory or dysphagic dermatomyositis
- Treat anti-MDA5 disease aggressively given rapidly progressive ILD risk
- Provide physiotherapy and monitor for inclusion body myositis if steroid-unresponsive
Drugs & doses
Prednisolone 1 mg/kg PO daily (up to 60-80 mg), tapering over months
Methylprednisolone 1 g IV daily for 3 days in severe disease
Methotrexate 15-25 mg weekly or azathioprine 2-3 mg/kg/day (steroid-sparing)
IVIG 2 g/kg over 2-5 days for refractory/dysphagic disease
Mycophenolate or rituximab for refractory or ILD-associated disease
Disposition
Specialist neuromuscular/rheumatology clinic. Admission for respiratory or swallowing compromise. Malignancy and ILD surveillance.
Complications & pitfalls
- Respiratory failure and interstitial lung disease
- Aspiration pneumonia from dysphagia
- Associated malignancy
- Steroid myopathy and immunosuppression complications
- Permanent muscle atrophy
Exam pearls
- Inclusion body myositis is distal, asymmetric and steroid-resistant; suspect it when treatment fails
- Dermatomyositis carries a significant malignancy risk; screen thoroughly
- Anti-MDA5 dermatomyositis can cause rapidly fatal lung disease and needs aggressive treatment
- A normal or only mildly raised creatine kinase does not exclude IBM
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.